Lyell Immunopharma, Inc. (LYEL) vs TRex Bio Inc. (TRXB)

Lyell Immunopharma, Inc. LYEL 14.82 −1.20%
TRex Bio Inc. TRXB 13.26 +2.08%

Lyell Immunopharma, Inc. and TRex Bio Inc. are both Biotechnology companies. Lyell Immunopharma, Inc. and TRex Bio Inc. are of similar size ($367.6M and $356.5M).

Metric	LYEL	TRXB	Biotechnology median
P/E	n/m	—	10.60
P/S	24,142.77	—	9.40
P/B	1.88	—	2.13
Price to free cash flow	n/m	—	25.18
EV/EBITDA	n/m	—	0.66
EV/Sales	12,335.70	—	9.02
Earnings yield	(84.75%)	—	(32.88%)
Free cash flow yield	(49.94%)	—	(23.13%)

Metric	LYEL	TRXB	Biotechnology median
Gross margin	100.00%	—	68.51%
Operating margin	(1,783,580.00%)	—	0.00%
Net margin	(1,701,066.67%)	—	0.00%
Free cash flow margin	(928,333.33%)	—	0.00%
Return on equity	(97.79%)	—	(51.96%)
Return on assets	(74.85%)	—	(46.06%)
Return on invested capital	(1,070.83%)	—	0.00%

Metric	LYEL	TRXB	Biotechnology median
Revenue growth (TTM)	(63.41%)	—	6.76%
EPS growth (last fiscal year)	38.70%	—	29.88%
Revenue growth, 5-year CAGR	(65.85%)	—	9.75%
Net income growth, 5-year CAGR	0.00%	—	0.00%

Metric	LYEL	TRXB	Biotechnology median
Debt to equity	0.00	—	0.00
Current ratio	4.02	—	4.97
Net debt to EBITDA	0.94	—	1.01

Metric	LYEL	TRXB	Biotechnology median
Dividend yield	—	—	0.41%
Payout ratio	—	—	—

Metric	LYEL	TRXB	Biotechnology median
Market cap	367.57m	356.52m	161.82m

Compare with another peer

Any metric, up to five companies and an Excel export Powerpack